Migraine Market Research Report - Global Forecast To 2022

Report / Search Code: MRFR/Pharma/1756-HCR  
Publish Date: November, 2019

Description:

Migraine Market information, by types (Episodic and Chronic), by treatment type (Preventive and Abortive), by drug class (Triptans, Ergots, and Others) - Global Forecast to 2022

Global Migraine Market Overview:

Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. According to a Medline article, around 12% of the U.S. population suffers from migraine headaches. The treatment of migraine headaches is eased by administration of preventive medications, to avoid the migraine attacks and abortive medications to relieve the strong and periodic pain.

Global Migraine Market Study objectives:

- To provide detail analysis of the market structure along with forecast for the next 5 years of the various segments and sub-segments of the global market.
- To provide insights about factors affecting the market growth
- To analyze the global Migraine market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To provide country level analysis of the market for segments by methods, by type, by treatment type and by drug class.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Migraine market.

Intended Audience:

- Global Migraine drugs manufacturers & Suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
- Academic Institutes and Universities

Global Migraine Market by Treatment Drugs:
Migraine Market Segments:

The Global market is majorly segmented on the basis of types, treatment types and drug class. Based on the type, the Migraine market is segmented into episodic and chronic. Based on treatment types, the Migraine market classified into preventive and abortive. Further on the basis of drugs, the Migraine market is classified into triptans, ergots and others.

Key players:
The major players listed in the market research report include Allergan, Impax Laboratories, Abbott Laboratories, Inc., Eisai Inc., Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, AstraZeneca plc, and GlaxoSmithKline plc.

The report for Global Migraine market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Contents:

<table>
<thead>
<tr>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Contents</td>
</tr>
<tr>
<td>1 INTRODUCTION</td>
</tr>
<tr>
<td>1.1 DEFINITION</td>
</tr>
<tr>
<td>1.2 SCOPE OF STUDY</td>
</tr>
<tr>
<td>1.2.1 RESEARCH OBJECTIVE</td>
</tr>
<tr>
<td>1.2.2 ASSUMPTIONS &amp; LIMITATIONS</td>
</tr>
<tr>
<td>1.2.2.1 ASSUMPTIONS</td>
</tr>
<tr>
<td>1.2.2.2 LIMITATIONS</td>
</tr>
<tr>
<td>1.3 MARKET STRUCTURE:</td>
</tr>
<tr>
<td>2 RESEARCH METHODOLOGY</td>
</tr>
<tr>
<td>2.1 RESEARCH PROCESS:</td>
</tr>
<tr>
<td>2.2 PRIMARY RESEARCH</td>
</tr>
<tr>
<td>2.3 SECONDARY RESEARCH:</td>
</tr>
<tr>
<td>3 MARKET DYNAMICS</td>
</tr>
<tr>
<td>3.1 DRIVERS</td>
</tr>
</tbody>
</table>
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS
4.1 PORTER'S FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY

5 GLOBAL MIGRAINE MARKET, BY TYPES
5.1 EPISODIC
5.2 CHRONIC

6. GLOBAL MIGRAINE MARKET, BY TREATMENT TYPE
6.1 ABORTIVE
6.2 PREVENTIVE

7. GLOBAL MIGRAINE MARKET, BY DRUG CLASS
7.1 TRiptANS
7.3 ERGOTS
7.3 OTHERS

8. GLOBAL MIGRAINE MARKET, BY REGION
8.1 NORTH AMERICA
8.1.1 INTRODUCTION
8.2 EUROPE
8.2.1 INTRODUCTION
8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION
8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION

9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MIGRAINE MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION

10 COMPANY PROFILE
10.1 ALLERGAN
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 ABBOTT LABORATORIES
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 GLAXOSMITHKLINE PLC
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 JOHNSON & JOHNSON
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 PFIZER, INC.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS

List of Tables
TABLE 1 GLOBAL MIGRAINE MARKET, BY TYPE, 2013-2022 (USD MILLION)
TABLE 2 GLOBAL MIGRAINE MARKET, BY TREATMENT TYPE, 2013-2022 (USD MILLION)
TABLE 3 GLOBAL MIGRAINE MARKET BY DRUG CLASS 2013-2022 (USD MILLION)
TABLE 4 GLOBAL MIGRAINE MARKET, BY REGION 2013-2022 (USD MILLION)

List of Figures
FIGURE 1 MIGRAINE MARKET RESEARCH PROCESS
FIGURE 2 MIGRAINE MARKET PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL MIGRAINE MARKET, BY TYPE
FIGURE 4 GLOBAL MIGRAINE MARKET, BY TREATMENT TYPE
FIGURE 5 GLOBAL MIGRAINE MARKET, BY DRUG CLASS
FIGURE 6 GLOBAL MIGRAINE MARKET, BY REGIONS
FIGURE 7 GLOBAL MIGRAINE MARKET: COMPANY SHARE ANALYSIS, 2015 (%)